COMP <GO>
PACS vs LLY // RSI-14 & 200D SMA MOMENTUM
PACS Group Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PACS 3
— LLY 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $47.81 (-3.76%) • MKT CAP: $7.87B
rsi-technicals
57.6
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PACS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PACS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.60% | 32.36% | -7.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 36.4x | -20.92 | PACS | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 2.30% | -0.19 | LLY | /fcf-yield <GO> |
| Operating Margin | 5.90% | 40.21% | -34.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 3.60% | 31.90% | -28.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 29.40% | 45.51% | -16.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 9.29 | -7.05 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | PACS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 57.6 | 77.9 | -20.23 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | PACS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 26.3x | +8.25 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.87B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PACS REV | LLY REV | PACS GROSS % | LLY GROSS % | PACS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.29B | $65.18B | 44.0% | 83.0% | $166.3M | $16.81B |
| FY 2024 | $4.09B | $45.04B | 44.0% | 81.3% | $183.4M | $8.82B |
| FY 2023 | $3.11B | $34.12B | 44.0% | 79.3% | -$76.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PACS // BETA 0.95
LLY // BETA 0.51